Lindong Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lindong Zhang has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Mengjun Zhang
Department of Gynecology, The Third Affiliated Hospital of Zhengzhou University
7 shared publicationsJialin Wang
Department of Orthopedics, the First Affiliated Hospital of Zhengzhou University
6 shared publicationsZidi Zhang
Department of Gynecology, The Third Affiliated Hospital of Zhengzhou University
5 shared publicationsHaodi Yue
Department of Center for Clinical Single Cell Biomedicine, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University
4 shared publications- Xin Zhao
The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China
2 shared publications - Yan Guo
Department of Oncology, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, Zhengzhou, China
2 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1681467
Targeting Cathepsin Z suppresses endometriosis via the AMPK/mTOR-mediated autophagy and apoptosis axis
Background: The key biomarkers, therapeutic targets, and pathological mechanisms of endometriosis are urgently needed to be elucidated. The role of CTSZ in EM needs to be clarified, and the potential regulatory mechanisms and corresponding therapeutic drugs of CTSZ need to be explored to demonstrate the feasibility of CTSZ as a biomarker and therapeutic target. Methods: Based on transcriptome sequencing of local clinical tissue samples and public data, the key pathogenic gene ( CTSZ ) was screened out using machine learning algorithms (LASSO and SVM-RFE), and the expression of CTSZ was evaluated at multiple levels. The effects of knocking down CTSZ on the proliferation and migration of endometriosis cell lines (12Z) were assessed. The effects of knocking down CTSZ on apoptosis, autophagy and AMPK/mTOR signaling pathways were predicted and investigated. Results: CTSZ was found to be abnormally overexpressed in sequencing data, endometriosis clinical tissue samples, and corresponding cell lines (12Z), suggesting it is a potential pathogenic gene. Knockdown of CTSZ significantly inhibited the proliferation and migration of 12Z. CTSZ may be related to key processes and proteins of apoptosis, autophagy and AMPK/mTOR signaling pathways. Knockdown of CTSZ significantly promoted apoptosis and autophagy by activating AMPK and subsequently inhibiting mTOR signaling. Conclusion: CTSZ is a potential pathogenic gene and therapeutic target. Its knockdown could activate AMPK and subsequently inhibit mTOR signaling, thereby inducing autophagy and synergistically promoting apoptosis, inhibiting proliferation and migration, and ultimately inhibiting endometriosis.
- 1 September 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1681467
Open AccessTargeting Cathepsin Z suppresses endometriosis via the AMPK/mTOR-mediated autophagy and apoptosis axis
Background: The key biomarkers, therapeutic targets, and pathological mechanisms of endometriosis are urgently needed to be elucidated. The role of CTSZ in EM needs to be clarified, and the potential regulatory mechanisms and corresponding therapeutic drugs of CTSZ need to be explored to demonstrate the feasibility of CTSZ as a biomarker and therapeutic target. Methods: Based on transcriptome sequencing of local clinical tissue samples and public data, the key pathogenic gene ( CTSZ ) was screened out using machine learning algorithms (LASSO and SVM-RFE), and the expression of CTSZ was evaluated at multiple levels. The effects of knocking down CTSZ on the proliferation and migration of endometriosis cell lines (12Z) were assessed. The effects of knocking down CTSZ on apoptosis, autophagy and AMPK/mTOR signaling pathways were predicted and investigated. Results: CTSZ was found to be abnormally overexpressed in sequencing data, endometriosis clinical tissue samples, and corresponding cell lines (12Z), suggesting it is a potential pathogenic gene. Knockdown of CTSZ significantly inhibited the proliferation and migration of 12Z. CTSZ may be related to key processes and proteins of apoptosis, autophagy and AMPK/mTOR signaling pathways. Knockdown of CTSZ significantly promoted apoptosis and autophagy by activating AMPK and subsequently inhibiting mTOR signaling. Conclusion: CTSZ is a potential pathogenic gene and therapeutic target. Its knockdown could activate AMPK and subsequently inhibit mTOR signaling, thereby inducing autophagy and synergistically promoting apoptosis, inhibiting proliferation and migration, and ultimately inhibiting endometriosis.
- 2 January 2026
- Published by Springer Nature in Functional & Integrative Genomics
- Vol. 26 (1) , 14
ETS Homologous Factor (EHF) and Gamma Linolenic Acid (GLA): novel strategies for early diagnosis and treatment of endometriosis
- 2 January 2026
- Published by Springer Nature in Functional & Integrative Genomics
- Vol. 26 (1) , 14
ETS Homologous Factor (EHF) and Gamma Linolenic Acid (GLA): novel strategies for early diagnosis and treatment of endometriosis
- Open Access
- 17 November 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 2115
Expression of ITGA3 in pan-cancer tissues and its relationship to prognosis and immune infiltration
Cancer constitutes a significant global health challenge, contributing to escalating socioeconomic burdens and necessitating the urgent identification of novel biomarkers and therapeutic targets. This study seeks to investigate the expression levels of integrin α3 (ITGA3) across various cancer types and its association with immune cell infiltration, thereby elucidating its potential role in cancer progression at the pan-cancer level. By employing expression profile data from The Cancer Genome Atlas (TCGA) and supplementary data from the Human Protein Atlas (HPA), we performed differential expression analysis, single-cell RNA expression analysis, Western blotting, immunohistochemical analysis, and subcellular immunofluorescence staining analysis to evaluate the expression levels and patterns of ITGA3 in diverse cancer types. Utilizing mutation analysis from cBioPortal, functional enrichment, and protein–protein interaction analysis from the STRING database, alongside six advanced immune cell abundance estimation algorithms—TIMER, xCell, MCP-counter, CIBERSORT, EPIC, and quanTIseq—we identified that ITGA3 exhibits differential expression across various cancer types. This expression is correlated with numerous clinical features, immune cell infiltration, immunotherapy response, and mutation burden, ultimately influencing patient prognosis. These findings underscore the potential regulatory role of ITGA3 within the tumor microenvironment and offer novel insights into its potential as a biomarker and therapeutic target in immunotherapy at the pan-cancer level. Future studies should verify the specific mechanisms of ITGA3 in cancer progression and the immune microenvironment.
- 17 November 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 2115
Open AccessExpression of ITGA3 in pan-cancer tissues and its relationship to prognosis and immune infiltration
Cancer constitutes a significant global health challenge, contributing to escalating socioeconomic burdens and necessitating the urgent identification of novel biomarkers and therapeutic targets. This study seeks to investigate the expression levels of integrin α3 (ITGA3) across various cancer types and its association with immune cell infiltration, thereby elucidating its potential role in cancer progression at the pan-cancer level. By employing expression profile data from The Cancer Genome Atlas (TCGA) and supplementary data from the Human Protein Atlas (HPA), we performed differential expression analysis, single-cell RNA expression analysis, Western blotting, immunohistochemical analysis, and subcellular immunofluorescence staining analysis to evaluate the expression levels and patterns of ITGA3 in diverse cancer types. Utilizing mutation analysis from cBioPortal, functional enrichment, and protein–protein interaction analysis from the STRING database, alongside six advanced immune cell abundance estimation algorithms—TIMER, xCell, MCP-counter, CIBERSORT, EPIC, and quanTIseq—we identified that ITGA3 exhibits differential expression across various cancer types. This expression is correlated with numerous clinical features, immune cell infiltration, immunotherapy response, and mutation burden, ultimately influencing patient prognosis. These findings underscore the potential regulatory role of ITGA3 within the tumor microenvironment and offer novel insights into its potential as a biomarker and therapeutic target in immunotherapy at the pan-cancer level. Future studies should verify the specific mechanisms of ITGA3 in cancer progression and the immune microenvironment.
- Open Access
- 5 May 2025
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 29 (9) , e70576
Unveiling the Role of PNMA2 in Endometriosis: From Proliferation and Apoptosis to Immunomodulation
Endometriosis is a chronic disease that jeopardises the quality of life of about 10% of women. The aim of this study was to investigate the expression, function, regulatory mechanism, and relationship with immune cell infiltration of PNMA2 in endometriosis. This study investigates the potential involvement and regulatory mechanisms of PNMA2 in the development of endometriosis through the integration of public data, machine learning, clinical sample transcriptome sequencing, and in vitro cell experiments. Cytological in vitro experiments were conducted to validate the impact of PNMA2 on the modulation of proliferation, migration, apoptosis, and autophagy in 12z cells. Rescue experiments were performed based on the autophagy activator ( RAPA ) to clarify the regulatory details of PNMA2 , apoptosis, and autophagy. The Ciberort algorithm was employed to discern the association between PNMA2 gene expression and more than 20 distinct immune cell infiltration types in endometriosis. The expression of PNMA2 exhibited a notable increase in individuals with endometriosis. Knockdown of PNMA2 inhibited the proliferation and migration of 12z cells. Knockdown of PNMA2 could directly promote apoptosis and could also inhibit autophagy and indirectly promote apoptosis. PNMA2 displayed associations with immune cell infiltration and immunomodulation. The present study demonstrated that the up‐regulation of PNMA2 was associated with malignant growth, anti‐apoptosis, and immunoregulation of human endometriotic cells. Therefore, PNMA2 may serve as a new diagnostic biomarker and a promising therapeutic target.
- 5 May 2025
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 29 (9) , e70576
Open AccessUnveiling the Role of PNMA2 in Endometriosis: From Proliferation and Apoptosis to Immunomodulation
Endometriosis is a chronic disease that jeopardises the quality of life of about 10% of women. The aim of this study was to investigate the expression, function, regulatory mechanism, and relationship with immune cell infiltration of PNMA2 in endometriosis. This study investigates the potential involvement and regulatory mechanisms of PNMA2 in the development of endometriosis through the integration of public data, machine learning, clinical sample transcriptome sequencing, and in vitro cell experiments. Cytological in vitro experiments were conducted to validate the impact of PNMA2 on the modulation of proliferation, migration, apoptosis, and autophagy in 12z cells. Rescue experiments were performed based on the autophagy activator ( RAPA ) to clarify the regulatory details of PNMA2 , apoptosis, and autophagy. The Ciberort algorithm was employed to discern the association between PNMA2 gene expression and more than 20 distinct immune cell infiltration types in endometriosis. The expression of PNMA2 exhibited a notable increase in individuals with endometriosis. Knockdown of PNMA2 inhibited the proliferation and migration of 12z cells. Knockdown of PNMA2 could directly promote apoptosis and could also inhibit autophagy and indirectly promote apoptosis. PNMA2 displayed associations with immune cell infiltration and immunomodulation. The present study demonstrated that the up‐regulation of PNMA2 was associated with malignant growth, anti‐apoptosis, and immunoregulation of human endometriotic cells. Therefore, PNMA2 may serve as a new diagnostic biomarker and a promising therapeutic target.
- Open Access
- 23 February 2024
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 300 (4) , 106793
5-Methylcytosine transferase NSUN2 drives NRF2-mediated ferroptosis resistance in non-small cell lung cancer
- 23 February 2024
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 300 (4) , 106793
Open Access5-Methylcytosine transferase NSUN2 drives NRF2-mediated ferroptosis resistance in non-small cell lung cancer
- Open Access
Diverse roles of UBE2S in cancer and therapy resistance: Biological functions and mechanisms
- Open Access
- 19 December 2023
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 16 (1) , 1-18
Activation of PI3K/AKT/mTOR signaling axis by UBE2S inhibits autophagy leading to cisplatin resistance in ovarian cancer
Background: Epithelial ovarian cancer (OC) is the fourth leading cause of cancer-related deaths in women, with a 5-year survival rate of 30%-50%. Platinum resistance is the chief culprit for the high recurrence and mortality rates. Several studies confirm that the metabolic regulation of ubiquitinating enzymes plays a vital role in platinum resistance in OC. Methods: In this study, we selected ubiquitin-conjugating enzyme E2S (UBE2S) as the candidate gene for validation. The levels of UBE2S expression were investigated using TCGA, GTEx, UALCAN, and HPA databases. In addition, the correlation between UBE2S and platinum resistance in OC was analyzed using data from TCGA. Cisplatin-resistant OC cell lines were generated and UBE2S was knocked down; the transfection efficiency was verified. Subsequently, the effects of knockdown of UBE2S on the proliferation and migration of cisplatin-resistant OC cells were examined through the CCK8, Ki-67 immunofluorescence, clone formation, wound healing, and transwell assays. In addition, the UBE2S gene was also validated in vivo by xenograft models in nude mice. Finally, the relationship between the UBE2S gene and autophagy and the possible underlying regulatory mechanism was preliminarily investigated through MDC and GFP-LC3-B autophagy detection and western blotting experiments. Most importantly, experimental validation of mTOR agonist reversion (the rescuse experiments) was also performed. Results: UBE2S was highly expressed in OC at both nucleic acid and protein levels. The results of immunohistochemistry showed that the level of UBE2S expression in platinum-resistant samples was significantly higher relative to the platinum-sensitive samples. By cell transfection experiments, knocking down of the UBE2S gene was found to inhibit the proliferation and migration of cisplatin-resistant OC cells. Moreover, the UBE2S gene could inhibit autophagy by activating the PI3K/AKT/mTOR signaling pathway to induce cisplatin resistance in OC in vivo and in vitro. Conclusion: In conclusion, we discovered a novel oncogene, UBE2S, which was associated with platinum response in OC, and examined its key role through bioinformatics and preliminary experiments. The findings may open up a new avenue for the evaluation and treatment of OC patients at high risk of cisplatin resistance.
- 19 December 2023
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 16 (1) , 1-18
Open AccessActivation of PI3K/AKT/mTOR signaling axis by UBE2S inhibits autophagy leading to cisplatin resistance in ovarian cancer
Background: Epithelial ovarian cancer (OC) is the fourth leading cause of cancer-related deaths in women, with a 5-year survival rate of 30%-50%. Platinum resistance is the chief culprit for the high recurrence and mortality rates. Several studies confirm that the metabolic regulation of ubiquitinating enzymes plays a vital role in platinum resistance in OC. Methods: In this study, we selected ubiquitin-conjugating enzyme E2S (UBE2S) as the candidate gene for validation. The levels of UBE2S expression were investigated using TCGA, GTEx, UALCAN, and HPA databases. In addition, the correlation between UBE2S and platinum resistance in OC was analyzed using data from TCGA. Cisplatin-resistant OC cell lines were generated and UBE2S was knocked down; the transfection efficiency was verified. Subsequently, the effects of knockdown of UBE2S on the proliferation and migration of cisplatin-resistant OC cells were examined through the CCK8, Ki-67 immunofluorescence, clone formation, wound healing, and transwell assays. In addition, the UBE2S gene was also validated in vivo by xenograft models in nude mice. Finally, the relationship between the UBE2S gene and autophagy and the possible underlying regulatory mechanism was preliminarily investigated through MDC and GFP-LC3-B autophagy detection and western blotting experiments. Most importantly, experimental validation of mTOR agonist reversion (the rescuse experiments) was also performed. Results: UBE2S was highly expressed in OC at both nucleic acid and protein levels. The results of immunohistochemistry showed that the level of UBE2S expression in platinum-resistant samples was significantly higher relative to the platinum-sensitive samples. By cell transfection experiments, knocking down of the UBE2S gene was found to inhibit the proliferation and migration of cisplatin-resistant OC cells. Moreover, the UBE2S gene could inhibit autophagy by activating the PI3K/AKT/mTOR signaling pathway to induce cisplatin resistance in OC in vivo and in vitro. Conclusion: In conclusion, we discovered a novel oncogene, UBE2S, which was associated with platinum response in OC, and examined its key role through bioinformatics and preliminary experiments. The findings may open up a new avenue for the evaluation and treatment of OC patients at high risk of cisplatin resistance.
- Open Access
- 30 August 2022
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 13, 918319
Identification of prognostic biomarkers in the CMTM family genes of human ovarian cancer through bioinformatics analysis and experimental verification
Background: Ovarian cancer (OV) is one of the most common gynecological malignancies worldwide, and its immunotherapy has considerable prospects. Multiple members of the CMTM family were aberrantly expressed in human cancers and controlled key malignant biological processes and immune regulation in cancer development. However, little is known about the function of this gene family in ovarian cancer, especially in terms of immunity.Methods: GEPIA, Oncomine, HPA, Kaplan–Meier plotter, cBioPortal, GeneMANIA, and TIMER were used to analyze the differential gene expression, prognostic value, genetic alterations, and alterations in the immune microenvironment of the CMTM family in patients with ovarian cancer. Importantly, RT-qPCR was used to verify the gene expression of the CMTM family.Results: CMTM1/3/4/6/7/8 showed abnormally high expression at the mRNA and protein levels in OV tissues based on the GEPIA and HPA databases. RT-qPCR showed that CMTM1/6/8 was highly expressed in ovarian cancer cell lines. IHC verified that CMTM8 is highly expressed in ovarian cancer tissues and is closely related to Ki-67. Survival analysis showed that high expression of CMTM1/2/3/5/8 can lead to a significant reduction in overall survival and progression-free survival. There were many types of genetic alterations in the CMTM family. Also, CMTM1/2/3/6 had a certain correlation with the changes in the immune microenvironment such as immune cell infiltration and immune checkpoint expression, which may be the potential mechanism of the CMTM family in ovarian cancer. IHC verified that CMTM6 is highly expressed in ovarian cancer tissues and is closely related to PD-L1.Conclusion: This study confirmed that the CMTM family has abnormal expression in ovarian cancer and CMTM8 can be used as a biomarker for prognostic evaluation. Also, the CMTM family may be used as a potential target for immunotherapy based on the suppression of immune checkpoints.
- 30 August 2022
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 13, 918319
Open AccessIdentification of prognostic biomarkers in the CMTM family genes of human ovarian cancer through bioinformatics analysis and experimental verification
Background: Ovarian cancer (OV) is one of the most common gynecological malignancies worldwide, and its immunotherapy has considerable prospects. Multiple members of the CMTM family were aberrantly expressed in human cancers and controlled key malignant biological processes and immune regulation in cancer development. However, little is known about the function of this gene family in ovarian cancer, especially in terms of immunity.Methods: GEPIA, Oncomine, HPA, Kaplan–Meier plotter, cBioPortal, GeneMANIA, and TIMER were used to analyze the differential gene expression, prognostic value, genetic alterations, and alterations in the immune microenvironment of the CMTM family in patients with ovarian cancer. Importantly, RT-qPCR was used to verify the gene expression of the CMTM family.Results: CMTM1/3/4/6/7/8 showed abnormally high expression at the mRNA and protein levels in OV tissues based on the GEPIA and HPA databases. RT-qPCR showed that CMTM1/6/8 was highly expressed in ovarian cancer cell lines. IHC verified that CMTM8 is highly expressed in ovarian cancer tissues and is closely related to Ki-67. Survival analysis showed that high expression of CMTM1/2/3/5/8 can lead to a significant reduction in overall survival and progression-free survival. There were many types of genetic alterations in the CMTM family. Also, CMTM1/2/3/6 had a certain correlation with the changes in the immune microenvironment such as immune cell infiltration and immune checkpoint expression, which may be the potential mechanism of the CMTM family in ovarian cancer. IHC verified that CMTM6 is highly expressed in ovarian cancer tissues and is closely related to PD-L1.Conclusion: This study confirmed that the CMTM family has abnormal expression in ovarian cancer and CMTM8 can be used as a biomarker for prognostic evaluation. Also, the CMTM family may be used as a potential target for immunotherapy based on the suppression of immune checkpoints.